Wave Life Sciences (WVE) Fundamental Analysis: Revenue, Earnings & Valuation

0.56 / 10

Underperform

Fundamental metrics are poor: revenue YoY down 60.5%, income‑tax ratio zero, and low asset‑MV and revenue‑MV differentials. Inventory turnover, receivables and fixed‑asset turnover score modestly, but overall rating is Underperform, suggesting challenging valuation.

Analysis Checks(5/10)

Revenue-MV

Value-2.93

Score1/3

Weight60.23%

1M Return5.06%

Total operating revenue (YoY growth rate %)

Value-60.55

Score1/3

Weight-13.84%

1M Return-1.40%

Inventory turnover ratio

Value106.57

Score3/3

Weight-6.45%

1M Return-0.67%

Accounts receivable turnover ratio

Value31.67

Score2/3

Weight-6.39%

1M Return-0.65%

PB-ROE

Value3.02

Score0/3

Weight46.71%

1M Return3.80%

Income tax / Total profit (%)

Value0.00

Score0/3

Weight-14.52%

1M Return-1.54%

Fixed assets turnover ratio

Value1.79

Score2/3

Weight-10.19%

1M Return-1.01%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-7.21%

1M Return-0.73%

Cost of sales ratio (%)

Value57.03

Score2/3

Weight-7.08%

1M Return-0.74%

Asset-MV

Value-0.55

Score0/3

Weight58.74%

1M Return4.88%

Is WVE undervalued or overvalued?

WVE scores 0.56/10 on fundamentals and holds a Premium valuation at present. Backed by its -54.97% ROE, -478.33% net margin, -5.89 P/E ratio, 2.29 P/B ratio, and -72.86% earnings growth, these metrics solidify its Underperform investment rating.